Cancer NetworkOriginal article
<![CDATA[Hypofractionated PMRT Shows Durable 10-Year Control in High-Risk Breast Cancer]]>
Data ReadoutpositivePositive
AI Analysis
Summary
10-year data from the CHN HYPOPMRT trial demonstrate that 3-week hypofractionated postmastectomy radiotherapy with nodal irradiation achieves durable locoregional control in high-risk breast cancer without increased severe late toxicity.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
10-year CHN HYPOPMRT data show 3-week postmastectomy radiotherapy with nodal irradiation maintains locoregional control without added severe late toxicity
Importance:6/10
Sentiment:
0.70
breast cancerpostmastectomy radiotherapyhypofractionatedlocoregional control10-year data
Read the original article
Published by Cancer Network on September 28, 2026 10:30 PM